Jordan Berlin

39.9k total citations · 9 hit papers
357 papers, 22.9k citations indexed

About

Jordan Berlin is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Jordan Berlin has authored 357 papers receiving a total of 22.9k indexed citations (citations by other indexed papers that have themselves been cited), including 281 papers in Oncology, 130 papers in Pulmonary and Respiratory Medicine and 66 papers in Molecular Biology. Recurrent topics in Jordan Berlin's work include Colorectal Cancer Treatments and Studies (118 papers), Pancreatic and Hepatic Oncology Research (100 papers) and Cancer Treatment and Pharmacology (64 papers). Jordan Berlin is often cited by papers focused on Colorectal Cancer Treatments and Studies (118 papers), Pancreatic and Hepatic Oncology Research (100 papers) and Cancer Treatment and Pharmacology (64 papers). Jordan Berlin collaborates with scholars based in United States, Germany and Spain. Jordan Berlin's co-authors include Fairooz F. Kabbinavar, Herbert I. Hurwitz, W. Heim, John D. Hainsworth, William Novotny, Louis Fehrenbacher, Eric Holmgren, Thomas H. Cartwright, Robert W. Ross and Ari David Baron and has published in prestigious journals such as Nature, New England Journal of Medicine and Nature Medicine.

In The Last Decade

Jordan Berlin

342 papers receiving 22.2k citations

Hit Papers

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin... 2002 2026 2010 2018 2004 2012 2002 2005 2003 2.5k 5.0k 7.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
    2004 8.4k citations Jordan Berlin et al. profile →
  2. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
    2012 1.3k citations Jordan Berlin et al. profile →
  3. Phase III Study of Gemcitabine in Combination With Fluorouracil Versus Gemcitabine Alone in Patients With Advanced Pancreatic Carcinoma: Eastern Cooperative Oncology Group Trial E2297
    2002 602 citations Jordan Berlin et al. Journal of Clinical Oncology profile →
  4. Bevacizumab in Combination With Fluorouracil and Leucovorin: An Active Regimen for First-Line Metastatic Colorectal Cancer
    2005 550 citations Jordan Berlin et al. Journal of Clinical Oncology profile →
  5. Superiority of Oxaliplatin and Fluorouracil-Leucovorin Compared With Either Therapy Alone in Patients With Progressive Colorectal Cancer After Irinotecan and Fluorouracil-Leucovorin: Interim Results of a Phase III Trial
    2003 510 citations Mace L. Rothenberg, Jordan Berlin et al. Journal of Clinical Oncology profile →
  6. Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical models
    2018 379 citations Jordan Berlin et al. profile →
  7. Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study
    2018 302 citations Dejan Juric, Jordi Rodón et al. Journal of Clinical Oncology profile →
  8. Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update
    2021 155 citations Jordan Berlin et al. Journal of Clinical Oncology profile →
  9. Management of Locally Advanced Rectal Cancer: ASCO Guideline
    2024 47 citations Jordan Berlin et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jordan Berlin United States 60 15.3k 6.6k 6.3k 5.0k 3.4k 357 22.9k
Herbert I. Hurwitz United States 71 17.8k 1.2× 8.0k 1.2× 7.8k 1.2× 4.8k 1.0× 3.7k 1.1× 319 26.8k
Marc Ychou France 59 16.1k 1.1× 4.2k 0.6× 7.7k 1.2× 5.1k 1.0× 4.8k 1.4× 322 22.1k
Filippo de Braud Italy 74 17.9k 1.2× 5.7k 0.9× 8.8k 1.4× 3.7k 0.7× 5.6k 1.7× 754 26.7k
Anthony T.�C. Chan Hong Kong 86 11.7k 0.8× 7.8k 1.2× 5.6k 0.9× 6.1k 1.2× 7.2k 2.1× 456 27.6k
Stefano Cascinu Italy 63 11.2k 0.7× 4.2k 0.6× 7.3k 1.2× 3.4k 0.7× 3.4k 1.0× 648 18.3k
Jennifer J. Knox Canada 59 7.7k 0.5× 4.7k 0.7× 8.3k 1.3× 3.9k 0.8× 4.4k 1.3× 382 17.5k
J. Wanders Netherlands 38 11.1k 0.7× 4.2k 0.6× 7.9k 1.3× 2.8k 0.6× 3.0k 0.9× 132 19.6k
Joon Oh Park South Korea 54 9.2k 0.6× 4.5k 0.7× 7.6k 1.2× 2.9k 0.6× 4.3k 1.3× 387 16.2k
Andrés Cervantes Spain 68 18.1k 1.2× 4.2k 0.6× 9.4k 1.5× 3.3k 0.7× 8.4k 2.5× 468 27.8k
Yoon‐Koo Kang South Korea 69 12.3k 0.8× 5.2k 0.8× 13.6k 2.2× 3.0k 0.6× 6.9k 2.0× 550 26.2k

Countries citing papers authored by Jordan Berlin

Since Specialization
Citations

This map shows the geographic impact of Jordan Berlin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jordan Berlin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jordan Berlin more than expected).

Fields of papers citing papers by Jordan Berlin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jordan Berlin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jordan Berlin. The network helps show where Jordan Berlin may publish in the future.

Co-authorship network of co-authors of Jordan Berlin

This figure shows the co-authorship network connecting the top 25 collaborators of Jordan Berlin. A scholar is included among the top collaborators of Jordan Berlin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jordan Berlin. Jordan Berlin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Williams, Vonetta M., Christopher L. Hallemeier, Krishan R. Jethwa, et al.. (2025). Executive Summary of the American Radium Society Appropriate Use Criteria for Management of Squamous Cell Carcinoma of the Cervical Esophagus. American Journal of Clinical Oncology. 48(4). 163–179.
2.
Qi, Changsong, Lin Shen, Thierry André, et al.. (2025). Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer. European Journal of Cancer. 220. 115338–115338. 5 indexed citations
3.
Fakih, Marwan, Wael A. Harb, Daruka Mahadevan, et al.. (2023). Safety and efficacy of the tumor-selective adenovirus enadenotucirev, in combination with nivolumab, in patients with advanced/metastatic epithelial cancer: a phase I clinical trial (SPICE). Journal for ImmunoTherapy of Cancer. 11(4). e006561–e006561. 28 indexed citations
4.
Jethwa, Krishan R., Edward Kim, Jordan Berlin, et al.. (2023). Executive Summary of the American Radium Society Appropriate Use Criteria for Neoadjuvant Therapy for Nonmetastatic Pancreatic Adenocarcinoma. American Journal of Clinical Oncology. 47(4). 185–199. 1 indexed citations
5.
Wang, Fei, Xiang Shu, Tuya Pal, et al.. (2022). Racial/Ethnic Disparities in Mortality Related to Access to Care for Major Cancers in the United States. Cancers. 14(14). 3390–3390. 15 indexed citations
6.
Das, Satya, Chanjuan Shi, Liping Du, Kamran Idrees, & Jordan Berlin. (2018). Adenocarcinoma Ex-Goblet Cell: a Retrospective Experience. Journal of Gastrointestinal Cancer. 50(4). 709–715. 4 indexed citations
7.
Goff, Laura W., Nilofer S. Azad, Stacey Stein, et al.. (2018). Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer. Investigational New Drugs. 37(2). 315–322. 13 indexed citations
8.
Juric, Dejan, Jordi Rodón, Josep Tabernero, et al.. (2018). Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. Journal of Clinical Oncology. 36(13). 1291–1299. 302 indexed citations breakdown →
9.
Heist, Rebecca S., Michael J. Guarino, Gregory A. Masters, et al.. (2017). Therapy of Advanced Non–Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan. Journal of Clinical Oncology. 35(24). 2790–2797. 139 indexed citations
10.
Goff, Laura W., Roger B. Cohen, Jordan Berlin, et al.. (2015). A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors. Clinical Cancer Research. 22(9). 2146–2154. 26 indexed citations
11.
Thota, Ramya, James M. Pauff, & Jordan Berlin. (2014). Treatment of metastatic pancreatic adenocarcinoma: a review.. PubMed. 28(1). 70–4. 96 indexed citations
12.
Puzanov, Igor, Colin R. Lindsay, Laura W. Goff, et al.. (2014). A Phase I Study of Continuous Oral Dosing of OSI-906, a Dual Inhibitor of Insulin-Like Growth Factor-1 and Insulin Receptors, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 21(4). 701–711. 78 indexed citations
13.
LoRusso, Patricia, Pasi A. Jänne, Moacyr Oliveira, et al.. (2013). Phase I Study of U3-1287, a Fully Human Anti-HER3 Monoclonal Antibody, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 19(11). 3078–3087. 74 indexed citations
14.
Cushman‐Vokoun, Allison M., Daniel G. Stover, Zhiguo Zhao, et al.. (2013). Clinical Utility of KRAS and BRAF Mutations in a Cohort of Patients With Colorectal Neoplasms Submitted for Microsatellite Instability Testing. Clinical Colorectal Cancer. 12(3). 168–178. 35 indexed citations
15.
Schwarz, Roderich E., Jordan Berlin, Heinz Josef Lenz, et al.. (2012). Systemic cytotoxic and biological therapies of colorectal liver metastases: expert consensus statement. HPB. 15(2). 106–115. 40 indexed citations
16.
Berlin, Jordan, Johanna C. Bendell, Lowell L. Hart, et al.. (2012). A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer. Clinical Cancer Research. 19(1). 258–267. 143 indexed citations
17.
LoRusso, Patricia, Antonio Jimeno, Grace K. Dy, et al.. (2011). Pharmacokinetic Dose-Scheduling Study of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors. Clinical Cancer Research. 17(17). 5774–5782. 74 indexed citations
18.
Puzanov, Igor, Wooin Lee, Alice P. Chen, et al.. (2011). Phase I Pharmacokinetic and Pharmacodynamic Study of SJG-136, a Novel DNA Sequence Selective Minor Groove Cross-linking Agent, in Advanced Solid Tumors. Clinical Cancer Research. 17(11). 3794–3802. 35 indexed citations
19.
Vo, Kevin D., et al.. (2011). Targeting notch pathway enhances rapamycin antitumor activity in pancreas cancers through PTEN phosphorylation. Molecular Cancer. 10(1). 138–138. 53 indexed citations
20.
Ellard, Susan, Mace L. Rothenberg, Roger Cohen, et al.. (2009). Abstract #3603: ARRY-334543 in ErbB2 positive metastatic breast cancer and other ErbB expressing-cancers: experience from expansion cohorts on a phase I study. Cancer Research. 69. 3603–3603. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Herbert I. Hurwitz Breakdown of academic impact, for papers by Marc Ychou Breakdown of academic impact, for papers by Filippo de Braud Breakdown of academic impact, for papers by Anthony T.�C. Chan Breakdown of academic impact, for papers by Stefano Cascinu Breakdown of academic impact, for papers by Jennifer J. Knox Breakdown of academic impact, for papers by J. Wanders Breakdown of academic impact, for papers by Joon Oh Park Breakdown of academic impact, for papers by Andrés Cervantes Breakdown of academic impact, for papers by Yoon‐Koo Kang
Rankless by CCL
2026